CSTL Castle Biosciences Inc
Price (delayed)
$30.7
Market cap
$851.52M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.12
Enterprise value
$791.14M
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently
Highlights
The net income has surged by 97% year-on-year and by 90% since the previous quarter
CSTL's EPS has surged by 96% year-on-year and by 89% since the previous quarter
The debt has soared by 75% YoY
Castle Biosciences's quick ratio has decreased by 12% QoQ
Key stats
What are the main financial stats of CSTL
Market
Valuations
Earnings
Shares outstanding
27.74M
Market cap
$851.52M
Enterprise value
$791.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
2
Price to sales (P/S)
2.95
EV/EBIT
N/A
EV/EBITDA
84.55
EV/Sales
2.75
Revenue
$287.59M
EBIT
-$3.73M
EBITDA
$9.36M
Free cash flow
$20.15M
Per share
Balance sheet
Liquidity
EPS
-$0.12
Free cash flow per share
$0.73
Book value per share
$15.35
Revenue per share
$10.4
TBVPS
$13.55
Total assets
$487.31M
Total liabilities
$63.42M
Debt
$25.19M
Equity
$423.89M
Working capital
$280.95M
Debt to equity
0.06
Current ratio
8.12
Quick ratio
7.78
Net debt/EBITDA
-6.45
Margins
Efficiency
Dividend
EBITDA margin
3.3%
Gross margin
81.9%
Net margin
-1.1%
Operating margin
-5.5%
Return on assets
-0.7%
Return on equity
-0.8%
Return on invested capital
-1.6%
Return on capital employed
-0.8%
Return on sales
-1.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSTL stock price
How has the Castle Biosciences stock price performed over time
Intraday
-1.76%
1 week
-1.06%
1 month
13.75%
1 year
83.94%
YTD
42.26%
QTD
41.02%
Financial performance
How have Castle Biosciences's revenue and profit performed over time
Revenue
$287.59M
Gross profit
$235.43M
Operating income
-$15.76M
Net income
-$3.1M
Gross margin
81.9%
Net margin
-1.1%
The net margin has soared by 98% YoY and by 91% QoQ
The net income has surged by 97% year-on-year and by 90% since the previous quarter
The operating margin has surged by 91% year-on-year and by 67% since the previous quarter
The operating income has soared by 84% YoY and by 62% from the previous quarter
Growth
What is Castle Biosciences's growth rate over time
Valuation
What is Castle Biosciences stock price valuation
P/E
N/A
P/B
2
P/S
2.95
EV/EBIT
N/A
EV/EBITDA
84.55
EV/Sales
2.75
CSTL's EPS has surged by 96% year-on-year and by 89% since the previous quarter
CSTL's price to book (P/B) is 46% higher than its last 4 quarters average of 1.4 but 32% lower than its 5-year quarterly average of 3.0
The equity is up by 12% year-on-year and by 5% since the previous quarter
CSTL's revenue has soared by 72% YoY and by 15% from the previous quarter
The P/S is 68% below the 5-year quarterly average of 9.4 but 25% above the last 4 quarters average of 2.4
Efficiency
How efficient is Castle Biosciences business performance
CSTL's return on sales has surged by 98% year-on-year and by 89% since the previous quarter
Castle Biosciences's return on invested capital has surged by 97% YoY and by 89% QoQ
Castle Biosciences's return on assets has surged by 97% YoY and by 90% QoQ
The ROE has soared by 96% YoY and by 90% QoQ
Dividends
What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSTL.
Financial health
How did Castle Biosciences financials performed over time
The total liabilities has grown by 36% year-on-year and by 13% since the previous quarter
Castle Biosciences's total assets has increased by 15% YoY and by 6% QoQ
The debt is 94% lower than the equity
The debt has soared by 75% YoY
CSTL's debt to equity has surged by 50% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.